Literature DB >> 12379884

Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers.

Gerd P Pfeifer1, Mikhail F Denissenko, Magali Olivier, Natalia Tretyakova, Stephen S Hecht, Pierre Hainaut.   

Abstract

It is estimated that cigarette smoking kills over 1 000 000 people each year by causing lung cancer as well as many other neoplasmas. p53 mutations are frequent in tobacco-related cancers and the mutation load is often higher in cancers from smokers than from nonsmokers. In lung cancers, the p53 mutational patterns are different between smokers and nonsmokers with an excess of G to T transversions in smoking-associated cancers. The prevalence of G to T transversions is 30% in smokers' lung cancer but only 12% in lung cancers of nonsmokers. A similar trend exists, albeit less marked, in laryngeal cancers and in head and neck cancers. This type of mutation is infrequent in most other tumors aside from hepatocellular carcinoma. At several p53 mutational hotspots common to all cancers, such as codons 248 and 273, a large fraction of the mutations are G to T events in lung cancers but are almost exclusively G to A transitions in non-tobacco-related cancers. Two important classes of tobacco smoke carcinogens are the polycyclic aromatic hydrocarbons (PAH) and the nicotine-derived nitrosamines. Recent studies have indicated that there is a strong coincidence of G to T transversion hotspots in lung cancers and sites of preferential formation of PAH adducts along the p53 gene. Endogenously methylated CpG dinucleotides are the preferred sites for G to T transversions, accounting for more than 50% of such mutations in lung tumors. The same dinucleotide, when present within CpG-methylated mutational reporter genes, is the target of G to T transversion hotspots in cells exposed to the model PAH compound benzo[a]pyrene-7,8-diol-9,10-epoxide. As summarized here, a number of other tobacco smoke carcinogens also can cause G to T transversion mutations. The available data suggest that p53 mutations in lung cancers can be attributed to direct DNA damage from cigarette smoke carcinogens rather than to selection of pre-existing endogenous mutations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379884     DOI: 10.1038/sj.onc.1205803

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  362 in total

1.  Bulky DNA adducts in white blood cells: a pooled analysis of 3,600 subjects.

Authors:  Fulvio Ricceri; Roger W Godschalk; Marco Peluso; David H Phillips; Antonio Agudo; Panagiotis Georgiadis; Steffen Loft; Anne Tjonneland; Ole Raaschou-Nielsen; Domenico Palli; Frederica Perera; Roel Vermeulen; Emanuela Taioli; Radim J Sram; Armelle Munnia; Fabio Rosa; Alessandra Allione; Giuseppe Matullo; Paolo Vineis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-04       Impact factor: 4.254

2.  Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system.

Authors:  Yashodhar P Bhandary; Shwetha K Shetty; Amarnath S Marudamuthu; Margaret R Gyetko; Steven Idell; Mehrnaz Gharaee-Kermani; Rashmi S Shetty; Barry C Starcher; Sreerama Shetty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-02       Impact factor: 5.464

3.  Detection of 7-(2'-carboxyethyl)guanine but not 7-carboxymethylguanine in human liver DNA.

Authors:  Guang Cheng; Mingyao Wang; Peter W Villalta; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

Review 4.  Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research.

Authors:  Yewei Liu; Ting Yin; Yuanbo Feng; Marlein Miranda Cona; Gang Huang; Jianjun Liu; Shaoli Song; Yansheng Jiang; Qian Xia; Johannes V Swinnen; Guy Bormans; Uwe Himmelreich; Raymond Oyen; Yicheng Ni
Journal:  Quant Imaging Med Surg       Date:  2015-10

Review 5.  Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.

Authors:  Lizza E Hendriks; Etienne Rouleau; Benjamin Besse
Journal:  Transl Lung Cancer Res       Date:  2018-12

6.  The Nonbulky DNA Lesions Spiroiminodihydantoin and 5-Guanidinohydantoin Significantly Block Human RNA Polymerase II Elongation in Vitro.

Authors:  Marina Kolbanovskiy; Moinuddin A Chowdhury; Aditi Nadkarni; Suse Broyde; Nicholas E Geacintov; David A Scicchitano; Vladimir Shafirovich
Journal:  Biochemistry       Date:  2017-06-07       Impact factor: 3.162

7.  MUC1 in macrophage: contributions to cigarette smoke-induced lung cancer.

Authors:  Xiuling Xu; Mabel T Padilla; Bilan Li; Alexandria Wells; Kosuke Kato; Carmen Tellez; Steven A Belinsky; Kwang Chul Kim; Yong Lin
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

Review 8.  Epidemiology of lung cancer.

Authors:  Carole A Ridge; Aoife M McErlean; Michelle S Ginsberg
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

Review 9.  Clonal expansion in non-cancer tissues.

Authors:  Nobuyuki Kakiuchi; Seishi Ogawa
Journal:  Nat Rev Cancer       Date:  2021-02-24       Impact factor: 60.716

10.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.